Corcept Therapeutics (CORT) Misses Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $85.86 -20.13%
Revenue Growth %: +56.0%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +56.0%
Financial Fact:
Loss from operations: 3.07M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q1 EPS of ($0.06), $0.09 worse than the analyst estimate of $0.03. Revenue for the quarter came in at $27.6 million versus the consensus estimate of $25.53 million.
GUIDANCE:
Corcept Therapeutics sees FY2017 revenue of $125-135 million, versus the consensus of $124 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Corcept Therapeutics (CORT) spreader of 2500 contracts of January 120 and 160 calls
- Genmab stock surges 9% following positive phase 3 ovarian cancer trial results
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
